

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 31/415, 9/20, 9/48, 9/50, 9/00		A1	(11) International Publication Number: WO 00/33835
			(43) International Publication Date: 15 June 2000 (15.06.00)
(21) International Application Number: PCT/EP99/10454			(81) Designated States: AE, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 1 December 1999 (01.12.99)			
(30) Priority Data: 98403037.9 4 December 1998 (04.12.98) EP			
(71) Applicant (<i>for all designated States except US</i>): SANOFI-SYNTHELABO [FR/FR]; 174, avenue de France, F-75013 Paris (FR).			
(72) Inventors; and (75) Inventors/Applicants (<i>for US only</i>): ALAUX, Gérard [FR/FR]; 33, rue du Roussillon, Val des Quatre Pignons, F-78650 Beynes (FR). LEWIS, Gareth [GB/FR]; 39, avenue de Paris, F-91410 Dourdan (FR). ANDRE, Frédéric [FR/FR]; 14 bis du Clos de Massy, F-92160 Antony (FR).			
(74) Agent: THOURET-LEMAITRE, Elisabeth; Sanofi-Synthelabo, 174, avenue de France, F-75013 Paris (FR).			Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: CONTROLLED-RELEASE DOSAGE FORMS COMPRISING ZOLPIDEM OR A SALT THEREOF			
(57) Abstract <p>The present invention relates to controlled-release dosage forms of zolpidem or salts thereof adapted to release zolpidem over a predetermined time period, according to a biphasic profile of dissolution, where the first phase is an immediate release phase and the second phase is a prolonged release phase and particular embodiments thereof intended to avoid abuse.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

CONTROLLED-RELEASE DOSAGE FORMS COMPRISING ZOLPIDEM OR A
SALT THEREOF

The present invention relates to controlled-release dosage
5 forms comprising zolpidem or salts thereof.

EP 173 928 discloses an oral pharmaceutical controlled
release preparation which has a biphasic release profile of
a pharmacologically active agent, comprising a core
10 containing the active agent and a coating applied thereon,
wherein the coating consists of a film-forming polymer
which is insoluble in water and gastro-intestinal fluids
and a water-soluble pore-creating material also including
the active agent.

15 EP 361 910 discloses granules which have a spray-dried
substance carrying an adsorbed pharmaceutical and a layer
comprising a pharmaceutically acceptable excipient and a
pharmaceutical.

20 GB 2 245 492 discloses an orally administrable programmed
release (i.e. release after a predetermined delay)
pharmaceutical preparation comprising a core coated with a
hydrophobic material and a surfactant.

25 Zolpidem is a suitable short acting hypnotic for the
controlled-release dosage form according to the present
invention. Zolpidem is a hypnotic from the therapeutical
class of imidazopyridines. It is administered orally by
30 means of a tablet or other solid dosage form.
Zolpidem acts rapidly. Indeed pharmacokinetic and
pharmacodynamic data show that zolpidem has both a rapid
absorption and onset of hypnotic action. Its
bioavailability is 70% following oral administration and
35 demonstrates linear kinetics in the therapeutical dose
range, which lies between 5 and 10 mg in conventional
forms, peak plasma concentration is reached at between 0.5
and 3 hours, the elimination half-life is short, with a
mean of 2.4 hours and a duration of action of up to 6

hours.

For reasons of simplicity, in the absence of contrary indication, within the whole description "zolpidem" or the "drug" means zolpidem *per se* as well as its salts.

- 5 The preferred salt of zolpidem is zolpidem hemitartrate.

Up to now, according to the rapidity of action of zolpidem, only immediate release dosage forms were developed, which disintegrate rapidly in the gastro-intestinal tract,
10 dissolve in the fluid of the gastrointestinal tract and undergo systemic absorption, where zolpidem, can exert its pharmacological effect and induce sleep of the patient.

The new dosage forms according to the present invention
15 enable to sustain release over a period compatible with the desired time of sleep and the time needed for elimination of the drug from the human body to a sufficiently low level.

20 Therefore, as a first object, the present invention provides controlled-release dosage forms comprising zolpidem or salts thereof adapted to release over a predetermined time period, according to a biphasic profile of dissolution, where the first phase is an immediate
25 release phase and the second phase is a prolonged release phase.

The "total amount of drug" means the quantity by weight of the drug comprised in the whole dosage form according to
30 the invention.

The first phase or immediate release phase is that part of the dissolution profile from 0 to 30 minutes in a suitable *in vitro* dissolution test. A suitable dissolution test is
35 for example one of the method described in example 1: method where measurement is carried out in a type II dissolution apparatus according to U.S. pharmacopoeia in aqueous buffer at 37°C, or variations on this as well known to one who is skilled in the art. The proportion of the

drug dissolved during this phase is the proportion of the total amount of the drug which is dissolved at 30 minutes. In an advantageous embodiment of the dosage forms according to the present invention 90% or more of that part of the
5 drug allotted for the first phase is dissolved in 20 minutes and more preferably in 15 minutes.

The second phase or prolonged release phase is that part of the dissolution profile which is after 30 minutes, measured
10 in a suitable *in vitro* dissolution test, such as described in example 1. The present invention then proposes dosage forms of the drug whose complete dissolution time for the second phase is between 2 and 6 hours, and preferably between 2.25 and 3.5 hours.

15 The profile of the second, prolonged release phase is defined by the percentage released at times T_1 , T_2 , and T_3 , defined as follows.

T_1 is the beginning of the second phase of drug release,
20 and is equal to 30 minutes.

T_3 is near the end of the second phase of drug release, and is the time at which 85% of the drug allotted for the second phase is released.

T_2 is the time at which 50% of the drug allotted for the
25 second phase is released. For example, if 50% of the total amount of drug is released at 30 minutes, there is 50% remaining for the second phase of release. T_3 is therefore the time for 92.5% dissolution [$50\% + 0.85 \times 50\%$], and T_2 is the time for 75% dissolution.

30 The second phase can represent a profile of release proportional to the square root of time, according to the equation proposed by T. Higuchi, *J. Pharm. Sci.* 52, 1145 (1963), sometimes called matrix release, where $(T_2 - T_1) = 0.35(T_3 - T_1)$. More advantageously the second phase can be
35 first-order release where $(T_2 - T_1) = 0.37(T_3 - T_1)$. Still more advantageously the second phase can represent a profile of order zero or a sigmoidal profile. A profile of order zero is one where the release rate is constant or

near-constant, and $(T_2 - T_1) = 0.59(T_3 - T_1)$. A sigmoidal profile is one where the release rate in the second phase accelerates so $(T_2 - T_1) > 0.59(T_3 - T_1)$. Profiles intermediate between these different types are also
5 covered.

The rapid release in the first phase induces the immediate sleep of the patient and the second phase allows the drug blood level to be maintained at or below the peak level,
10 but higher than the level obtained with an immediate release dosage form, at the same time after dosing, with the objective of maintaining sleep.

The present invention then proposes dosage forms of
15 zolpidem or a salt thereof whose complete dissolution time, defined as the time for release of 90% of the total amount of drug is between 2 and 6 hours and preferably between 2.25 and 3.5 hours.

20 40 to 70% of the total amount of drug can be released during the immediate release phase, preferably between 50 and 60%.

An example of such an *in vitro* release profile is given in
25 figure 1, where 60% of the total amount of drug is released during the immediate release phase, and the second phase is zero order with 90% of the total amount of drug dissolved in 3 hours. Further examples of such profiles are shown in figure 2, where 50% of the total amount of drug is
30 dissolved during the immediate release phase, and the second phase release is according to three other types of profile; release proportional to square root of time (matrix release), first order release, and a sigmoidal release profile.

35

As a second object, the present invention provides controlled-release dosage forms of zolpidem or salts thereof, characterised in that they comprise two kinds of pharmaceutical entities of drug: one immediate release

entity and one prolonged release entity. The drug dissolved during the immediate release phase (before 30 minutes) is contained within the immediate release entity, and that liberated in the prolonged release phase (after 30 minutes) is contained within the prolonged release entity.

Small quantities of the drug in a formulation for rapid release can be retained in the formulation and thus may be released at a time after 30 minutes from the beginning of the dissolution, and are thus included in the prolonged release phase. Similarly, small quantities of the drug incorporated in the prolonged release pharmaceutical entity may be released before 30 minutes, and thus form part of the immediate release phase.

According to the present invention, the proportion of the drug contained within the immediate release entity and dissolved within 30 minutes is at least 90%. And the proportion of the drug contained within the prolonged release entity and released within 30 minutes is comprised between 0 and 35%, and preferably between 0 and 25%.

Among dosage forms able to match the requirement of a biphasic profile and to comprise the two kinds of pharmaceutical entities defined above, the following may be cited: capsules, tablets, multilayer tablets, multicoated tablets.

The immediate release entity shall be understood in the present invention as a single pharmaceutical immediate release unit like for example an immediate release tablet or pellet, or several such units formulated into a capsule or a tablet ; as an immediate release matrix in a tablet ; as an immediate release layer, that can be incorporated in a multilayer tablet ; as an immediate release coating layer in a multicoated tablet or pellet.

The prolonged release entity shall be understood in the present invention as a pharmaceutical prolonged release unit such as, for example, a prolonged release tablet or

pellet, or several such units formulated into a capsule or a tablet ; as a prolonged release layer, that can be incorporated in a multilayer tablet ; as a prolonged release core or a prolonged release coating layer in a multicoated tablet ; as prolonged release pellets within a disintegrating tablet.

Dosage forms where the immediate release entity and the prolonged release entity are administered simultaneously but separately are also encompassed in the present invention.

List of figures:

Figure 1 shows an example of a *in vitro* biphasic release profile, where the immediate release phase is 60% of the total amount of zolpidem, and the second phase is zero order with 90% of the total amount of zolpidem dissolved in 3 hours.

Figure 2 shows an examples of biphasic *in vitro* release profiles, where 50% is dissolved in the first phase, and the second phase release is (i) proportional to the square root of time (continuous line), (ii) first order (dotted line), and (iii) a sigmoid release profile (dashed line).

Figure 3 shows an *in vitro* dissolution profile of the tablets of example 1, in 0.01 M hydrochloric acid and in pH 6.8 phosphate buffer, as described in example 1.

Figure 4 shows an *in vitro* dissolution profile of the tablets of comparative example 1, in 0.01 M hydrochloric acid and in pH 6.8 phosphate buffer, as described in comparative example 1.

Figure 5 shows the results of a single dose pharmacokinetic study comparing the immediate tablet formulation of example 2 and the combination of an immediate release tablet and a prolonged release tablet of example 3.

Figure 6 shows the dissolution profile of a mixture of immediate release and prolonged release spheroids of example 4, in 0.01 M hydrochloric acid.

- 5 Figure 7 shows bilayer and multilayer tablets. (a) Bilayer tablet consisting of one immediate release layer and one prolonged release layer. (b) Triple layer tablet consisting of two outer immediate release layers and one inner prolonged release layer. (c) Triple layer tablets
10 consisting of an outer immediate release layer, an inner prolonged release layer, and an outer layer not containing active substance, modulating the release profile. (d) Triple layer tablets consisting of an outer immediate release layer, an outer prolonged release layer, and an
15 inner layer not containing active substance, modulating the release profile.

Figure 8 shows the dissolution profile of the bilayer tablet of example 6, in 0.01 M hydrochloric acid, and in pH
20 6.8 and pH 7.5 phosphate buffers.

Figure 9 shows the dissolution profiles of the bilayer tablet and of the combination of an immediate release and a prolonged release tablet of comparative example 2, in
25 0.01 M hydrochloric acid.

Figure 10 shows the dissolution profile of the bilayer tablet of comparative example 3, in 0.01 M hydrochloric acid and in pH 6.8 phosphate buffer.

30

Figure 11 shows the dissolution profile of the bilayer tablet of example 8, in 0.01 M hydrochloric acid.

The dosage forms according to the invention typically
35 contain from 4 to 16 mg of zolpidem as zolpidem base, and preferably 6 to 12 mg of zolpidem as zolpidem base. The zolpidem may be incorporated as the base, or as a pharmaceutically acceptable salt of zolpidem. Among dosage forms comprising a salt of zolpidem rather than the

zolpidem base, according to the invention, those comprising zolpidem hemitartrate are especially preferred.

In advantageous embodiments, dosage forms may be formulated
5 in order to obtain in the second phase a dissolution independent of the pH. The preferred manner to achieve such a dissolution, in the case of basic drugs like zolpidem is to add a pharmaceutically acceptable organic acid into the dosage form, according to methods known from one skilled in
10 the art. Such dosage forms are preferred.

These pharmaceutically acceptable organic acid can be chosen for example among maleic, tartaric, malic, fumaric, lactic, citric, adipic or succinic acid and their acid
15 isomers, where these exist. According to the invention, acids particularly preferred are tartaric, fumaric, citric, and succinic and their acid salts.

Various formulations, not limiting the scope of the present
20 invention, illustrating the invention are described hereafter:

(1) A capsule comprising one or more immediate release tablets and one or more prolonged release tablets:
25 Immediate release tablets may be prepared by direct compression of mixtures of the drug or salts thereof with diluents, such as microcrystalline cellulose, mannitol, sorbitol, and lactose. Other functional excipients such as disintegrants and lubricants can be added. Choice of these
30 functional excipients as well as diluent is well known to anyone skilled in the art. Alternatively tablets may be prepared by granulation with water of a mixture of the drug or salts thereof with suitable diluents, disintegrant and binding polymer ; calibration and drying of the granulate ;
35 addition of a lubricant, followed by compression on a tableting machine. The methods used are those generally described in the pharmaceutical literature, see for example, B. B. Sheth, F. J. Bandelin and R. JF. Shangraw, Compressed Tablets, in Pharmaceutical Dosage Forms:

Tablets, Vol 1. edited by H. A. Lieberman and L. Lachman, Dekker N.Y. (1980).

Prolonged release tablets can be prepared by coating immediate release tablets with a diffusion limiting polymer coating. Suitable polymers can be chosen among ethyl cellulose, methyl methacrylate copolymers, such as Eudragit® RS, Eudragit® RL, Eudragit® NE commercialized by Röhm Pharma. Coating methods can consist in spraying a solution of the polymer on the tablets, either in a pan coater or a fluid bed coating apparatus. The solvent may be organic or aqueous, depending on the nature of the polymer used. Coating methods are described in the following works: J.M. Bakan, Microencapsulation, in L. Lachman, H. Lieberlman and J.L. Kanig (Eds.) The Theory and Practice of Industrial Pharmacy, Lea & Febinger, Philadelphia, USA, 1986 ; J.M. McGinity, Aqueous polymer coatings for Pharmaceutical Dosage Forms, Dekker NY, 1989.

Alternatively prolonged release tablets can be prepared by incorporating matrix-forming excipients into the formulation, and omitting disintegrants. Such matrix-forming excipients may be hydrophilic polymers, which include hydroxypropylmethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, and which swell in contact with aqueous liquids, and control release of the drug by diffusion through the swollen polymer network, and are incorporated at a level between 10 and 30% by weight with respect to that of the prolonged release tablet.

Otherwise the matrix forming excipient may be a lipidic substance, such as hydrogenated castor oil, or carnuba wax, incorporated at a level between 10 and 40% by weight with respect to that of the prolonged release tablet.

Prolonged release tablets can be formulated, as zolpidem is a basic drug optionnally with a pharmaceutically acceptable organic acid, chosen from the list given above so as to maintain the micro-pH of the tablet during dissolution in the neutral pH conditions of the small intestine.

(2) A capsule comprising a mixture of prolonged release

pellets and immediate release pellets:

- The immediate release pellets may be prepared by deposition of the drug suspended in water or an organic solvent such as ethanol with hydroxypropylmethylcellulose or povidone or
5 another suitable polymer to act as a binder, onto a spherical granule. A fluid bed coating apparatus is generally used. Particles may be agglomerated to form spherical granules or pellets, in a high speed mixer granulator, or rotary fluid bed agglomerator. These methods
10 are described by K.W.Olson and A.M.Mehta, *Int.J.Pharm.Tech&.Prod.Mfr.* 6 18-24, 1985. Pellets may be also prepared by extrusion of wet masses or melts followed by spheronisation, for example as described in C. Vervaet, L. Baert & J. P. Remon *Int.J.Pharm.* 116 (1995) 131-146.
- 15 Excipients used are typically those with plastic qualities such as microcrystalline cellulose, but also mannitol. Small quantities of a polymeric binder are generally added. Surfactants such as sodium dodecyl sulphate may also be incorporated to give easier extrusion.
- 20 Prolonged release pellets are prepared by coating immediate release pellets in the same way as described for the tablets. Coating may be carried out, for example, in coating pans or in fluid bed coater-driers. The amount and composition of the coating is adjusted from that used in
25 the tablet, to reduce the permeability of the coating in order to take into account the far greater surface for diffusion in the pellets.
- Prolonged release pellets can, as zolpidem is a basic drug, contain a pharmaceutically acceptable organic acid so as to
30 maintain the micro-pH of the interior of the pellet during dissolution in the neutral pH conditions of the small intestine.
- Alternatively, as zolpidem is a basic drug, prolonged release pellets may be coated with a pH sensitive membrane,
35 containing polymers soluble at neutral pH and impermeable at acid pH, such as Eudragit® S, allowing increased permeation by the drug at pH 5 and above, to compensate for the decreased solubility of the drug at higher pH values. Alternatively sustained release pellets and immediate

release powder.

(3) A tablet comprising a number of prolonged release coated pellets comprising the drug imbedded in a matrix
5 also comprising the drug:

Alternatively the tablet may consist of a mixture of prolonged release coated pellets and of immediate release non-coated pellets comprising the drug, imbedded in a drug-free matrix.

10 Alternatively the prolonged release coated pellets may be furthermore coated with a layer comprising the drug and other excipients allowing immediate release from that layer, imbedded in a drug-free matrix.

The matrix surrounding the pellets should preferably be
15 formulated so that the compression into tablets does not interfere with the integrity of the membrane surrounding the pellets. On contact with fluid the tablet disintegrates, releasing the drug rapidly, from the matrix, or the immediate release pellets, or from the immediate
20 release pellet coating, and then releasing the drug from the prolonged release pellets slowly. The pellet may be formulated with a pharmaceutically acceptable organic acid so as to maintain the micro-pH of the pellet during dissolution in the neutral pH conditions of the small
25 intestine.

(4) A multilayer tablet comprising:

(i) one or two prolonged release layers, comprising the drug and a hydrophilic polymer (preferably a cellulose
30 derivative),

(ii) one or more immediate release layers comprising the drug,

and possibly,

(iii) another layer not comprising the drug, but
35 comprising hydrophilic polymers, such as hydroxypropylcellulose, hydroxypropylcellulose, hydroxyethylcellulose or soluble diluents, such as lactose, sorbitol, mannitol, or hydrophilic polymers and soluble excipients, which layer modulates release

of the drug from the prolonged release layer.
Each layer contains other excipients, so as to give
suitable properties for compression, lubrication, binding
as is well known to one skilled in the art. Examples of
5 such bilayer and multilayer tablets are shown in figure 7a-
d, where immediate release layers are designated by i,
prolonged release layers by p and layers modulating the
release profile by m.

10 (5) A multicoated tablet comprising:

- (i) a core comprising the drug and as zolpidem is a
basic drugs, optionally a pharmaceutically acceptable
organic acid to maintain constant pH,
- (ii) a polymer coating layer giving slow release of the
15 drug from this core,
- (iii) a coating layer comprising the drug which is
released rapidly or immediately on contact of the
dosage form with fluid.

Each portion of the tablet, in particular the inner core,
20 can contain other excipients, so as to give suitable
properties for compression, lubrication, and binding as
is well known to one skilled in the art. Methods for making
both multilayered and multicoated tablets are described by
W.C. Gunsel, Compression coated and layer tablets in
25 Pharmaceutical Dosage Forms: Tablets, Vol 1. edited by H.
A. Lieberman and L. Lachman, Dekker N.Y. (1980).

As other particular embodiments encompassed within the
scope of the present invention, pharmaceutical compositions
30 intended to avoid abuse may be cited.

Indeed it is known that some drugs and in particular
hypnotics intended for legitimate oral use have the
potential for abuse.

One way of substantially reducing or even eliminating this
35 potential for drug abuse for the pharmaceutical
formulations that are objects of the present invention is
to provide pharmaceutical compositions for oral
administration comprising zolpidem capable at the same time
of:

- liberating the active principle according to a biphasic *in vitro* profile as described above, following normal administration and,
- if it is introduced in a drink, whether or not containing
5 alcohol, generating visual change or changes in the
appearance of the drink. This visual change or changes are intended to avoid administration of the active principle to a person in the said drink without his or her knowledge.

- 10 These visual changes, according to the present invention include all means of indicating the presence of the said composition in a drink. The following may be cited as methods for inducing visual changes: inclusion of colouring excipients, floating of the composition at the surface of
15 the drink, formation of insoluble particles on the surface of the drink, on the brim of the glass, in the drink and/or on the bottom of the glass or a combination thereof. The drink, eventually with alcohol, may for example consist of coffee, tea, wine, fortified wine, spirits, liqueurs,
20 hot or cold chocolate-flavoured drinks, all gaseous alcoholic or not-alcoholic drinks, all cocktails or mixtures of fruit juice, milk, cream, ...

- Floating of the composition can be achieved by an
25 effervescence which can be obtained by means of a effervescence generator, as described hereinafter. In addition to these effervescent properties, the composition can present viscosity increasing properties appearing on contact with the drink. Thus when the bubbles
30 are formed, they are "trapped" and the composition swells. The lowering of the density contributes to maintaining the pharmaceutical composition at the surface of the drink. Such a viscosity may be obtained by one or more gelating substances. Hydrophilic excipients are particularly
35 suitable as gel-forming substances as set forth beneath.

Particles may be obtained by association of a lipophilic and a hydrophilic excipient, useful for the floating as described above. A list of suitable lipophilic excipients

is set forth beneath.

The composition according to this particular embodiment of the present invention can liberate particules even if the composition does not float or not immediately.

The effervescence generator can be a carbon dioxide generator system. It can comprise a suitable carbon dioxide generator agent and a pharmaceutically acceptable acid.

The carbon dioxide generator agent is normally a carbonate or bicarbonate of an alkali or alkaline earth metal or an amino acid. Calcium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, L-lysine carbonate, arginine carbonate or sodium sesquicarbonate may be cited as carbon dioxide generator agents.

The acid may be an acid anhydride, a monocarboxylic acid, a polycarboxylic acid or a partial salt of a polycarboxylic acid. More particularly citric, tartaric, ascorbic, fumaric, nicotinic, acetylsalicylic, maleic, adipic, succinic, malic, malonic acid may be chosen or glutaric anhydride, citric anhydride, monosodium citrate and succinic anhydride.

The carbon dioxide generator agent may be constituted by a mixture of carbon dioxide generating agents cited above.

In such a carbon dioxide generator system, the content of acidic compound is generally chosen such as the ratio between the number of moles in the said acidic compound with respect to the number of moles in the said carbon dioxide generator agent is between 1 and 2.

The gel forming substances can consist of one or more hydrophilic excipients provoking the swelling of the composition and the trapping of the gas released.

In order to form insoluble particles, one or more lipophilic excipients are added to the hydrophilic excipient.

The process of effervescence and formation of particles

generate viscous agglomerates which float and stick to the glass. This process can last between 0.5 and 25 minutes depending on the type of drink.

5 Among lipophilic excipients the following may be cited: glycerol stearates, palmitostearates and behenates; hydrogenated vegetable oils and their derivatives; vegetable and animal wax and their derivatives; hydrogenated castor oils and their derivatives and cetylic
10 esters and alcohols.

Among hydrophilic excipients the following may be cited: cellulose derivatives, hydroxyethylcellulose, hydroxypropylcellulose (molecular mass from 50 to 1250
15 kDa), hydroxypropylmethylcellulose (molecular mass from 10 to 1500 kDa), carboxymethylcellulose and sodium carboxymethylcellulose; vegetable gums and their derivatives; derivatives of alginic acid; polyethyleneglycols and their derivatives; starches and their derivatives; silica, polymethacrylates and acrylic
20 acid and methacrylate copolymers.

One of the constituents of the gel forming substance can be chosen as being less soluble in alcohol.

A colouring excipient can be advantageously added as giving
25 rise to visual change preventing abuse. It can colour simultaneously the liquid or the particles or one independantly of the other.

Among suitable colouring excipients the following may be cited : indigotine, cochineal carminic acid, yellow orange
30 S, allura red AC, iron oxides, curcumin, riboflavin, tartrazine, quinoline yellow, azorubine, amaranth, carmines, erythrosine, red 2G, patented blue V, glittering blue FCF, chlorophylls, copper complexes of chlorophylls, green S, caramel, glittering black BN, carbo medicinalis
35 vegetabilis, brown FK and HT, carotenoids, Annatto extracts, paprika extracts, lycopene, lutein, canthaxanthin, beetroot red, anthocyanes, calcium carbonate, titanium dioxide, aluminium, silver, gold or litholrubin BK or any other colouring excipient suitable

for an oral administration..

These visual means of preventing abuse may comprise a distinct pharmaceutical entity, not containing active
5 substance, along with the immediate release and the sustained release entities, that comprise the pharmaceutical form, or they may be incorporated in one of these two entities. Yet a third method is to incorporate all or certain of them into a separate entity and at the
10 same time add certain to the immediate or sustained release entity.

The method of incorporation of abuse resistance as described above will depend on the type of formulation. In the case of tablet formulations described above, including
15 that of tablets enclosed inside a capsule, the abuse resistance conferring substances (colouring matter, effervescent couple...) may be included within the immediate release entity of the formulation.

Alternatively in the case of multilayer tablets and
20 immediate tablets within a capsule they may be incorporated as a separate layer not containing active substance, but with the abuse resistance conferring substances. Such a layer may be added to the sustained release tablet or tablets within a capsule provided the said tablet is
25 formulated as a matrix and is not coated with a coating conferring the sustained release properties.

In the case of a capsule containing controlled release pellets and immediate release pellets or granulate, abuse resistance conferring substances with the exception of an
30 effervescent couple may be incorporated in the immediate release entity or added separately.

The examples which follow illustrate the invention without limiting it:

Example 1: prolonged release tablet comprising 10 mg zolpidem hemitartrate.

The first four of the following materials were mixed together, granulated with water, dried and calibrated. The granulate was then mixed with the magnesium stearate and compressed to a mass of 120 mg per tablet, using a rotary tableting machine.

10	zolpidem hemitartrate	8.3 %
	lactose	86.6 %
	citric acid	2.5 %
	hydroxypropylmethylcellulose 606 ¹	2.1 %
	magnesium stearate	0.5 %

15 ¹ Pharmacoat 606, commercialized by Shin-Ensu Co

Tablets were coated, in an Accelacota pan coater, with a sufficient quantity of the following mixture to obtain the desired dissolution profile.

	ethylcellulose ¹	2.0 %
	diethylphthalate	0.4 %
25	hydroxypropylmethylcellulose 606	2.0 %
	isopropanol	47.8 %
	dichloromethane	47.8 %

¹ Ethocel, commercialized by Dow Chemical Co.

The *in vitro* dissolution profiles of the tablets were established using the Apparatus II of the United States Pharmacopoeia. Two dissolution media were employed: 900 ml hydrochloric acid 0.01 M and 900 ml of a pH 6.8 potassium phosphate 0.05 M buffer, maintained at 37 ± 0.5°C. Stirring was by the paddle method (50 rpm). The percentage dissolved was determined by measurement of the UV absorbance at 270 nm (continuous sampling by a peristaltic pump in a closed system). The results are shown in figure 3.

Comparative example 1: prolonged release tablet without acid comprising 10 mg zolpidem hemitartrate.

- 5 Tablets were manufactured according to the same method as example 1, having the following composition:

	zolpidem hemitartrate	8.3 %
	lactose	89.1 %
10	hydroxypropylmethylcellulose 606	2.1 %
	magnesium stearate	0.5 %

- They were coated with a polymer mixture comprising 50% hydroxypropylmethylcellulose and 50% ethylcellulose. Their *in vitro* dissolution profiles of the tablets were
- 15 established by the method of example 1.
- The results are shown in figure 4. They show that prolonged release tablets comprising acid present a profile of dissolution independent from the pH.

20

Example 2: Immediate release tablet comprising 10 mg zolpidem hemitartrate.

- Tablets dosed at 10 mg zolpidem hemitartrate and with
- 25 unitary mass 120 mg were manufactured according to the same method as example 1, having the following composition:

	zolpidem hemitartrate	8.3 %
	lactose	75.8 %
30	microcrystalline cellulose ¹	10.0 %
	hydroxypropylmethylcellulose 606	2.1 %
	sodium carboxymethylcellulose ²	3.2 %
	magnesium stearate	0.6 %

- 35 ¹ Avicel, commercialized by FMC
- ² Primojel, commercialized by Avebe

- The dissolution of the tablets was tested according to the method described in example 1, in the 0.01 M hydrochloric
- 40 acid medium. 90% of the amount of zolpidem contained in the

immediate release tablet were released in less than 30 minutes.

The obtained immediate release tablets were administered orally to 6 healthy volunteers in a pharmacokinetics study. Two tablets were administered orally to each volunteer in a single dose study. Blood samples were taken at 30 min, 1, 2, 3, 4, 6, 8, 10 hours, and analysed for zolpidem. The results (median zolpidem plasma levels) are plotted in figure 5 (closed squares).

Example 3: Pharmaceutical form consisting of an immediate release tablet comprising 10 mg zolpidem hemitartrate according to example 2, and a prolonged release tablet comprising 10 mg zolpidem hemitartrate according to example 1, within a gelatin capsule.

A pharmacokinetic study of a coadministration of a prolonged release tablet and a immediate release tablet was carried out. One immediate release tablet and one prolonged release tablet each comprising 10 mg zolpidem, as described above were administered to the same 6 volunteers as in the study described in example 2. The results (median zolpidem plasma levels) are plotted in figure 5 (open squares). The results show rapid increase in zolpidem levels to give a peak at 30 minutes, the same as for the immediate release, but plasma levels from 3-6 hours after dosing which are higher than those obtained with the same dose (20 mg) of the immediate release formulation. The whole quantity of zolpidem is released in a maximum time of about 8 hours. The dissolution profile was identical to that of the addition of the dissolution profiles of example 1 and 2. Thus the immediate and prolonged release pharmaceutical entities each contained 10 mg zolpidem hemitartrate (50%) and the immediate release phase was 12.2 mg (61%) and the prolonged release phase was 7.8 mg (39%). The complete dissolution time (90% released) was 2 h. The profile parameters are : $T_3 = 2.12 \text{ h}$; $T_2 = 1.19 \text{ h}$; $(T_2 - T_1) = 0.43(T_3 - T_1)$, the profile being close to zero-order.

Example 4: Capsule comprising a mixture of immediate release pellets and coated prolonged release pellets.

- 5 A suspension comprising 100 g zolpidem hemitartrate and 100 g povidone, commercialized under the reference Plasdone K29/32 by BASF, in 670 g ethanol was prepared. 750 g of this suspension was sprayed onto 1060 g of 16-18 mesh microgranules in a fluid bed drier. Dissolution of zolpidem
10 was tested in 0.01 M hydrochloric acid, according to the method in example 1. 80% was dissolved in 2 minutes, and 100% was dissolved at 30 minutes.
- A solution comprising 25 g of methacrylate copolymer Eudragit® RL100, 143 g of methacrylate copolymer
15 Eudragit® RS100 (both commercialized by Röhm Pharma) and 18.7 g of ethyl citrate commercialized under trademark Eudrafex® by Röhm Pharma as plasticiser, was prepared in 1180 g of a 60:40 m/m isopropanol/acetone mixture. Pellets comprising zolpidem were coated with this polymer mixture,
20 by spraying in a fluid bed dryer, the final amount of coating being 20% by mass of the uncoated pellet mass. After maturation of the pellets at 35°C for 24 hours, a mixture of these coated pellets and the uncoated pellets previously described was prepared in the proportion 1 : 1
25 by zolpidem content, and were filled into gelatin capsules to give a total amount of zolpidem hemitartrate content per capsule of 15 mg (12 mg zolpidem base). The dissolution of capsules was tested by the method of example 1, the resulting profile being shown in figure 6.
- 30 Thus the immediate and prolonged release pharmaceutical entities each contained 7.5 mg zolpidem hemitartrate (50%). Because of the lag-time of about 1h before release from the prolonged release entity, the immediate release phase (60%) and the prolonged release phase (40%) corresponded exactly
35 to the entities. The complete dissolution time (90% released) was 3.17 h. The profile parameters are : $T_3 = 3.17 \text{ h}$; $T_2 = 1.68 \text{ h}$; $(T_2 - T_1) = 0.44(T_3 - T_1)$ and the profile was sigmoid in shape.

Example 5: Tablet comprising coated prolonged release pellets comprising 5 mg zolpidem hemitartrate within a fast-disintegrating matrix comprising 7.5 mg zolpidem hemitartrate.

Prolonged release coated pellets were manufactured as described in example 4. The pellets were then spray-coated using the same method with a layer of 20% by mass of microcrystalline cellulose. A granule of the following composition was then prepared, by wet granulation:

	zolpidem hemitartrate	8.4 %
	lactose	20.0 %
15	microcrystalline cellulose ¹	62.9 %
	hydroxypropylmethylcellulose 606	3.0 %
	crospovidone ²	5.0 %
	magnesium stearate	0.7 %

¹ Avicel, commercialized by FMC

² Kollidon CL, commercialized by BASF

This was mixed with the coated pellets in the proportion 3 parts of granulate to 2 parts of coated pellets (in terms of zolpidem content) and the mixture compressed into tablets dosed at 12.5 mg zolpidem hemitartrate (equivalent to 10 mg zolpidem base).

Example 6: Bilayer immediate/prolonged release tablet comprising 12.5 mg zolpidem hemitartrate.

Granulates were prepared by wet granulation according to the following compositions. The granulating process was that described in example 1:

	GRANULATE 1 (Immediate release)	
	zolpidem hemitartrate	4.4 %
	lactose 150 mesh	68.3 %
40	microcrystalline cellulose	20.0 %

	hydroxypropylmethylcellulose 606	2.5 %
	sodium carboxymethylcellulose	3.8 %
	magnesium stearate	1.0 %
5	GRANULATE 2 (prolonged release)	
	zolpidem hemitartrate	5.6 %
	lactose 150 mesh	40.0 %
	microcrystalline cellulose	20.0 %
	tartaric acid	8.4 %
10	hydroxypropylmethylcellulose ¹	25.0 %
	magnesium stearate	1.0 %

¹ Metolose 90SH4000, commercialized by Shin-Etsu

15 The mixtures were then compressed into bilayer tablets of the form shown in figure 7(a) using an alternative tablet press. Each tablet contained 12.5 mg zolpidem hemitartrate, the first immediate release layer with 125 mg of granulate 1 comprising 5.5 mg of zolpidem hemitartrate, and the

20 prolonged release layer with 125 mg granulate 2 comprising 7 mg zolpidem hemitartrate. The *in vitro* dissolution profiles of the tablets were established using the Apparatus 2 of the United States Pharmacopeia. Three dissolution media were employed: hydrochloric acid 0.01 M,

25 a pH 6.8 potassium phosphate 0.025 M buffer, and a pH 7.5 potassium phosphate 0.015 M buffer. The volume of dissolution medium was 500 ml, maintained at $37 \pm 0.5^\circ\text{C}$. Stirring was by the paddle method (75 rpm). A grill was placed in the bottom of each vessel, to prevent sticking of

30 the tablet to the glass surface. The percentage dissolved was determined by measurement of the UV absorbance at 310 nm (continuous sampling by a peristaltic pump in a closed system). The results are shown in figure 8. The dissolution profile is almost independent of pH between pH

35 1 and 6.8. Zolpidem continues to be released at pH 7.5, though at a significantly reduced rate. The immediate release entity contained 5.5 mg zolpidem hemitartrate (44%) and the prolonged release entity contained 7.5 mg zolpidem hemitartrate (56%). The complete

40 dissolution time (90% released) was 2.14 h. Because of release from the prolonged release pharmaceutical entity

from 0 to 0.5 h, the corresponding immediate release phase was 7.5 mg (60%) and the prolonged release phase was 5 mg (40%). The profile parameters are : $T_3 = 2.23$ h ; $T_2 = 1.38$ h ; $(T_2 - T_1) = 0.51(T_3 - T_1)$, the profile being zero-order.

Comparative example 2 : Comparison of the dissolution profile of a bilayer immediate/prolonged release tablet comprising 12.5 mg zolpidem hemitartrate with that of an immediate release and a prolonged release tablet of the same composition

Granulates were prepared by wet granulation according to the following compositions. The granulating process was that described in example 1:

	GRANULATE 1 (Immediate release)	
	zolpidem hemitartrate	6.0 %
20	lactose 150 mesh	66.7 %
	microcrystalline cellulose	20.0 %
	hydroxypropylmethylcellulose 606	2.5 %
	sodium carboxymethylcellulose	3.8 %
25	magnesium stearate	1.0 %
	GRANULATE 2 (prolonged release)	
	zolpidem hemitartrate	4.0 %
	lactose 150 mesh	55.0 %
	microcrystalline cellulose	20.0 %
30	hydroxypropylmethylcellulose ¹	20.0 %
	magnesium stearate	1.0 %

¹ Metolose 90SH4000, commercialized by Shin-Etsu

A portion of each granulate was compressed into bilayer tablets of the form shown in figure 7(a) using an alternative tablet press. Each tablet contained 12.5 mg zolpidem hemitartrate, the first immediate release layer with 125 mg of granulate 1 comprising 6.5 mg of zolpidem hemitartrate, and the prolonged release layer with 125 mg granulate 2 comprising 6 mg zolpidem hemitartrate. The

dissolution profile was tested using the Apparatus 2 of the United States Pharmacopeia. The dissolution medium was hydrochloric acid 0.01 M, maintained at $37 \pm 0.5^\circ\text{C}$. The volume was 500 ml and stirring was by the paddle method (75 rpm). The percentage dissolved was determined by measurement of the UV absorbance at 310 nm (continuous sampling by a peristaltic pump in a closed system). The results are shown in figure 9. The pH of the dissolution media had a marked affect on the profile, increased pH depressing the dissolution rate.

The remaining portions of each granulate of comparative example 2 were each compressed into tablets mass 125 mg, the immediate release tablet (granulate 1) comprising 7.5 mg zolpidem hemitartrate, and the prolonged release tablet comprising 5 mg zolpidem hemitartrate. The *in vitro* dissolution profiles of the tablets were established by the method of example 1.

The resulting profiles are shown on figure 9. Surprisingly, the presence of the immediate layer had a significant effect on the dissolution of the hydrophilic matrix prolonged release layer in the bilayer tablet, and whereas the dissolution profile of the separate tablets was the sum of the profiles of the separate tablets, the prolonged release phase of the bilayer tablet was considerably slower than in the case of the separate tablets.

Comparative example 3 : pH dependence of the dissolution profile of a bilayer tablet comprising 12.5 mg zolpidem hemitartrate without acid in the prolonged release layer

Granulates similar to those of example 6 were prepared, the only difference being that in the case of granulation 2 (prolonged release) the tartaric acid was missed out and replaced in the formulation by lactose (48.4%). The mixtures were then compressed into bilayer tablets of the form shown in figure 7(a) using an alternative tablet

press, as for example 6: The *in vitro* dissolution profiles of the tablets were established as for example 6, using two dissolution media : hydrochloric acid 0.01 M and pH 6.8 potassium phosphate 0.025 M buffer. The results are shown in figure 10. The dissolution profile in 0.01 M hydrochloric acid is very close to that of the formulation with acid (example 6), but the rate at pH 6.8 is much decreased.

10

Example 7: Three-layer immediate/prolonged release tablet comprising 12.5 mg zolpidem hemitartrate.

15 Granulates were prepared by the method of example 1 according to the following compositions:

	LAYER 1 (immediate release)	
	zolpidem hemitartrate	5.0 %
20	lactose 150 mesh	67.7 %
	microcrystalline cellulose	20.0 %
	hydroxypropylmethylcellulose 606	2.5 %
	sodium carboxymethylcellulose	3.8 %
	magnesium stearate	1.0 %
25	LAYER 2 (non-active)	
	lactose (spray dried)	60.0 %
	microcrystalline cellulose	24.0 %
	tartaric acid	10.0 %
30	hydroxyethylcellulose	5.0 %
	magnesium stearate	1.0 %
	LAYER 3 (prolonged release)	
	zolpidem hemitartrate	6.0 %
35	lactose 150 mesh	40.0 %
	microcrystalline cellulose	19.0 %
	tartaric acid	9.0 %
	hydroxypropylmethylcellulose ¹	25.0 %
40	magnesium stearate	1.0 %

¹ Metolose 90SH4000, commercialized by Shin-Etsu

They were compressed as described in example 6 into 3 layer tablets, of the form shown in figure 7(d) layer 1 comprising 100 mg of the granulate 1, with 5 mg zolpidem hemitartrate, layer 2 (the middle layer) comprising 100 mg of the granulate 2, and layer 3 comprising 125 mg of the granulate 3 and 7.5 mg zolpidem hemitartrate.

Example 8: Coated bilayer immediate/prolonged release tablet comprising 10 mg zolpidem hemitartrate and containing an efferevescent couple and a dye in the immediate release layer.

Mixtures were prepared according to the compositions shown below. The powder mixture 1 for the immediate layer was prepared by dry mixing of the first eight ingredients. the remaining three ingredients are than added. The granulate 2 for the prolonged release layer was prepared by granulation with water of the first five components, the reamining two components being mixed with the granulate after drying and sieving.

	POWDER MIXTURE 1 (Immediate release)	
	zolpidem hemitartrate	3.6 %
25	anhydrous lactose	11.3 %
	microcrystalline cellulose	24.3 %
	povidone K30	5.0 %
	tartaric acid	23.0 %
	sodium bicarbonate	25.0 %
30	sodium carboxymethylcellulose	3.0 %
	Indigotine W6004	0.8 %
	sodium dodecyl sulphate	2.0 %
	colloidal silica	1.0 %
	magnesium stearate	1.0 %
35	GRANULATE 2 (prolonged release)	
	zolpidem hemitartrate	4.4 %
	lactose 150 mesh	36.0 %
	tartaric acid	8.4 %
40	microcrystalline cellulose	20.0 %
	hydroxypropylmethylcellulose ¹	30.0 %

27

colloidal silica	0.2 %
magnesium stearate	1.0 %

¹ Metolose 90SH4000, commercialized by Shin-Etsu

5

The mixtures were then compressed into bilayer tablets of the form shown in figure 7(a) using a Manesty BL tablet press. Each tablet contained 10 mg zolpidem hemitartrate, the first immediate release layer with 125 mg of powder mixture 1 comprising 4.5 mg of zolpidem hemitartrate, and the prolonged release layer with 125 mg granulate 2 comprising 5.5 mg zolpidem hemitartrate.

A film coating (4% with respect to tablet mass) of the following composition, was applied as a 20% dispersion in absolute alcohol, using a coating turbine (Glatt GC300).

copovidone ¹	12 %
ethylcellulose	12 %
20 titanium dioxide	46 %
Talc	30 %

¹Kollidon VA64, commercialized by BASF

25 The dissolution profile of the tablets was determined in 0.01M hydrochloric acid, using the apparatus and method described in example 6. The results are shown in figure 11.

Example 9: Coated trilayer immediate/prolonged release tablet comprising 10 mg zolpidem hemitartrate and containing an effervescent couple and a dye.

Mixtures were prepared according to the compositions shown below. The powder mixture 1 for the immediate layer was prepared by dry mixing of the first eight ingredients. the remaining three ingredients are than added. The granulate 2 for the prolonged release layer was prepared by granulation with water of the first five components, the reamining two components being mixed with the granulate after drying and sieving.

	POWDER MIXTURE 1 (Immediate release)	
	zolpidem hemitartrate	4.0 %
	microcrystalline cellulose	36.4 %
5	povidone K30	5.0 %
	tartaric acid	23.0 %
	sodium bicarbonate	25.0 %
	sodium carboxymethylcellulose	3.0 %
	black iron oxide	0.3 %
10	Indigotine	0.8 %
	sodium dodecyl sulphate	1.0 %
	colloidal silica	1.0 %
	magnesium stearate	0.5 %
15	POWDER MIXTURE 2 (Anti-abuse)	
	microcrystalline cellulose	40.4 %
	povidone K30	5.0 %
	tartaric acid	23.0 %
	sodium bicarbonate	25.0 %
20	sodium carboxymethylcellulose	3.0 %
	black iron oxide	0.3 %
	Indigotine	0.8 %
	sodium dodecyl sulphate	1.0 %
	colloidal silica	1.0 %
25	magnesium stearate	0.5 %
	GRANULATE 3 (prolonged release)	
	zolpidem hemitartrate	4.0 %
	lactose 150 mesh	36.0 %
30	tartaric acid	8.4 %
	microcrystalline cellulose	20.4 %
	hydroxypropylmethylcellulose ¹	30.0 %
	colloidal silica	0.2 %
35	magnesium stearate	1.0 %

¹ Metolose 90SH4000, commercialized by Shin-Etsu

The mixtures were then compressed into trilayer tablets of the form shown in figure 7(d) - the layer not containing
 40 zolpidem, that is of granulate 2, being designated by m - using a Manesty BL tablet press. Each tablet contained 10 mg zolpidem hemitartrate. Each layer comprised 125 mg granulate or powder mixture, and the immediate release and

prolonged release layers both containing 5 mg of zolpidem hemitartrate.

The tablets were film coated as described in example 8.

5

Example 10: Dry-coated prolonged release tablet dosed at 15 mg zolpidem hemitartrate.

10 Granulates were prepared with the following composition, using the method described in example 1.

	GRANULATE 1 (Immediate release)	
	zolpidem hemitartrate	4.0 %
15	lactose 150 mesh	48.7 %
	microcrystalline cellulose	40.0 %
	hydroxypropylmethylcellulose 606	2.5 %
	sodium carboxymethylcellulose	3.8 %
	magnesium stearate	1.0 %
20		
	GRANULATE 2 (prolonged release)	
	zolpidem hemitartrate	7.2 %
	lactose 150 mesh	38.4 %
	microcrystalline cellulose	20.0 %
25	tartaric acid	8.4 %
	hydroxypropylmethylcellulose ¹	25.0 %
	magnesium stearate	1.0 %

¹ Metolose 90SH4000, commercialized by Shin-Etsu

30

The granulate 2 was compressed using an alternative tablet press to give prolonged release tablets of mass 125 mg dosed at 9 mg zolpidem hemitartrate. The tablets were dry coated with the granulate 1, the mass of dry coating being 150 mg, and the dosage of zolpidem hemitartrate in the coat being 6 mg.

35

Claims

1. A pharmaceutical composition comprising zolpidem or a salt thereof characterised in that it consists of a controlled-release dosage form adapted to release zolpidem or its salt over a predetermined time period, according to a biphasic *in vitro* profile of dissolution when measured in a type II dissolution apparatus according to U.S. Pharmacopoeia in aqueous buffer at 37°C, where the first phase is an immediate release phase and the second phase is a prolonged release phase.
2. A pharmaceutical composition according to claim 1, characterized in that the first phase has a maximum duration of 30 minutes.
3. A pharmaceutical composition according to claim 1 or 2 characterized in that the second phase has a profile of zero order release.
4. A pharmaceutical composition according to claim 1 or 2 characterized in that the second phase has a profile where the release is proportional to the square root of the time.
5. A pharmaceutical composition according to claim 1 or 2 characterized in that the second phase has a profile of first order release.
6. A pharmaceutical composition according to claim 1 or 2 characterized in that the second phase has a sigmoidal release profile.
7. A pharmaceutical composition according to any one of claims 1 to 6 characterized in that 40 to 70% of the total amount of zolpidem is released during the immediate release phase.
8. A pharmaceutical composition according to any one of claims 1 to 7 characterized in that the time for release of

90% of the total amount of zolpidem is between 2 and 6 hours.

9. A pharmaceutical composition comprising zolpidem or a salt thereof characterized in that it comprises two kinds of pharmaceutical entities: one immediate release entity and one prolonged release entity.
10. A pharmaceutical composition according to claim 9 characterized in that it consists in a dosage form chosen among capsules, tablets, multilayer tablets, multicoated tablets.
11. A pharmaceutical composition according to claim 9 or 10 characterized in that it consists of a capsule comprising one or more immediate release tablets and one or more prolonged release tablets.
12. A pharmaceutical composition according to claim 9 or 10 characterized in that it consists of a capsule comprising a mixture of prolonged release pellets and immediate release pellets.
13. A pharmaceutical composition according to claim 9 or 10 characterized in that it consists of a tablet comprising a number of prolonged release coated pellets comprising the drug imbedded in a matrix also comprising the drug.
14. A pharmaceutical composition according to claim 9 or 10 characterized in that it consists of a multilayer tablet comprising:
- (i) one or two prolonged release layers, comprising the drug and a hydrophilic polymer (preferably a cellulose derivative),
 - (ii) one or more immediate release layers comprising the drug, and possibly,
 - (iii) another layer not comprising the drug, but comprising hydrophilic polymers.

15. A pharmaceutical composition according to claim 9 or 10 characterized in that it consists of a multicoated tablet comprising:

- 5 (i) a core comprising the drug and optionally a pharmaceutically acceptable organic acid to maintain constant pH,
- (ii) a polymer coating layer giving slow release of the drug from this core,
- 10 (iii) a coating layer comprising the drug which is released rapidly or immediately on contact of the dosage form with fluid.

16. A pharmaceutical composition according to claim 9 characterized in that the immediate release entity and the
15 prolonged release entity are administered simultaneously but separately.

17. A pharmaceutical composition according to any one of claims 1 to 16 characterized in that the prolonged release
20 entity comprises a pharmaceutically acceptable organic acid which can be chosen among tartaric, malic, fumaric, lactic, citric, adipic or succinic acid and their acid salts, in the form of racemates or isomers.

25 18. A pharmaceutical composition according to any one of claims 1 to 17 characterized in that it is capable of generating visual change if it is introduced into a drink, whether or not containing alcohol,

30 19. A pharmaceutical composition according to claim 18 characterized in that the visual change consists of release of included colouring excipients, or floating of the composition at the surface of the drink, or formation of insoluble particles on the surface of the drink, on the
35 brim of the glass, in the drink and/or on the bottom of the glass or a combination thereof.

20. A pharmaceutical composition according to claim 19 characterized in that it comprises an effervescence

33.

generator, a hydrophilic excipient and optionnally a lipophilic excipient and a colouring excipient, taking the form alternatively of a tablet, a multilayer tablet or a capsule containing controlled release pellets and immediate
5 release pellets or granulates.

21. A pharmaceutical composition according to any one of claims 1 to 20 characterized in that zolpidem has the form of zolpidem hemitartrate.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/10454

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/415 A61K9/20 A61K9/48 A61K9/50 A61K9/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 173 928 A (AB LEO) 12 March 1986 (1986-03-12) claims 1,3,6 figure 1	1-21
A	EP 0 361 910 A (MAY & BECKER) 4 April 1990 (1990-04-04) claim 11 page 2, line 37 - line 44 page 3, line 5 - line 12 page 3, line 56 - page 4, line 1 example 10	1-21

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

11 April 2000

Date of mailing of the international search report

18/04/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3018

Authorized officer

Ventura Amat, A

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/10454

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB 2 245 492 A (ZAMBON) 8 January 1992 (1992-01-08) claims 1,15 page 7, line 20 - line 24 page 9, line 28 - page 10, line 10	1,9,10, 13,14, 17,18
A	WO 95 20947 A (RHONE-POULENC RORER) 10 August 1995 (1995-08-10) the whole document	1-21

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/EP 99/10454

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 173928	A	12-03-1986	AT 53490 T	15-06-1990
			AU 576891 B	08-09-1988
			AU 4693585 A	13-03-1986
			CA 1252723 A	18-04-1989
			DK 400685 A,B,	07-03-1986
			ES 546728 D	16-12-1986
			ES 8702138 A	16-03-1987
			FI 853406 A,B,	07-03-1986
			GR 852158 A	08-01-1986
			HU 40333 A,B	28-12-1986
			IE 58263 B	25-08-1993
			IL 76256 A	10-06-1990
			JP 2527713 B	28-08-1996
			JP 61112013 A	30-05-1986
			KR 9303114 B	19-04-1993
			NO 853407 A,B,	07-03-1986
			NZ 213245 A	30-06-1988
			PH 22119 A	01-06-1988
			PT 81092 A,B	01-10-1985
			US 4824678 A	25-04-1989
			ZA 8506547 A	30-04-1986
EP 361910	A	04-04-1990	AT 107854 T	15-07-1994
			AU 623177 B	07-05-1992
			AU 4241689 A	05-04-1990
			DE 68916497 D	04-08-1994
			DE 68916497 T	17-11-1994
			DK 481689 A	31-03-1990
			ES 2058546 T	01-11-1994
			FI 894611 A	31-03-1990
			HU 53282 A,B	28-10-1990
			IE 63875 B	14-06-1995
			IL 91836 A	29-12-1994
			JP 2180813 A	13-07-1990
			NO 893893 A	02-04-1990
			NZ 230836 A	26-07-1990
			PT 91857 A,B	30-03-1990
			US 5489439 A	06-02-1996
			YU 189289 A	30-04-1991
			ZA 8907440 A	25-07-1990
GB 2245492	A	08-01-1992	IT 1244867 B	12-09-1994
			IT 1244037 B	28-06-1994
			AT 400295 B	27-11-1995
			AT 131091 A	15-04-1995
			AU 638583 B	01-07-1993
			AU 8019991 A	09-01-1992
			BE 1004882 A	16-02-1993
			CA 2044398 A	05-01-1992
			CH 683498 A	31-03-1994
			DE 4122039 A	09-01-1992
			DK 129591 A	05-01-1992
			ES 2036457 B	01-03-1994
			FI 913248 A	05-01-1992
			FR 2664163 A	10-01-1992
			GR 91100283 A,B	26-08-1992
			HU 59591 A	29-06-1992
			HU 9500435 A	28-09-1995

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/EP 99/10454

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 2245492 A		IE 61651 B	16-11-1994
		IL 98525 A	23-07-1996
		JP 6024961 A	01-02-1994
		LU 87964 A	03-03-1992
		NL 9101161 A	03-02-1992
		NO 304579 B	18-01-1999
		PT 98188 A, B	29-05-1992
		SE 512373 C	06-03-2000
		SE 9102072 A	05-01-1992
		RU 2012330 C	15-05-1994
		US 5310558 A	10-05-1994
		US 5445828 A	29-08-1995
		US 5629017 A	13-05-1997
		ZA 9104724 A	27-05-1992
WO 9520947 A	10-08-1995	AT 177630 T	15-04-1999
		AU 696005 B	27-08-1998
		AU 1461695 A	21-08-1995
		CZ 9602260 A	15-01-1997
		DE 69508385 D	22-04-1999
		DE 69508385 T	26-08-1999
		EP 0742711 A	20-11-1996
		ES 2132626 T	16-08-1999
		FI 963025 A	31-07-1996
		GR 3029734 T	30-06-1999
		HU 74903 A	28-03-1997
		JP 9508410 T	26-08-1997
		NO 963202 A	30-09-1996
		NZ 278643 A	19-12-1997
		PL 315709 A	25-11-1996
		ZA 9500800 A	01-08-1996

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9




Figure 10




Figure 11

